Brief: Sensei Biotherapeutics Presents New Preclinical Data On Sns-103 Targeting ENTPDase1
18/04/2023 21:24
April 18 (Reuters) - Sensei Biotherapeutics Inc
SNSE.O :
* SENSEI BIOTHERAPEUTICS PRESENTS NEW PRECLINICAL DATA ON
SNS-103
TARGETING ENTPDASE1 (CD39) AT THE AMERICAN ASSOCIATION FOR
CANCER RESEARCH (AACR) ANNUAL MEETING 2023
* SENSEI BIOTHERAPEUTICS INC - INTENDS TO SELECT A LEAD
PRODUCT
CANDIDATE FOR SNS-103 IN 2023
Source text for Eikon: ID:nGNX8N5qdj
Further company coverage: SNSE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Faeth Therapeutics,
See all newsBrief: Sensei Biotherapeutics Announces Name Change To Faeth Therapeutics
Brief: Sensei Biotherapeutics Doses First Patient In Phase 1B/2 Trial Of Piktor In Hr+/Her2- Advanced Breast Cancer
Brief: Sensei Biotherapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)